Kevin A. Kriess

Array ( [id] => 17274495 [patent_doc_number] => 20210380693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => METHODS OF TREATING TUMOR [patent_app_type] => utility [patent_app_number] => 17/287838 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227194 [patent_doc_number] => 20210353750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => Methods of Treating Cancer [patent_app_type] => utility [patent_app_number] => 17/284242 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20074 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299552 [patent_doc_number] => 20210395391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => Dosage Regimen for TFPI Antagonists [patent_app_type] => utility [patent_app_number] => 17/283801 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18071599 [patent_doc_number] => 11530424 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-12-20 [patent_title] => Efficient CRISPR/HDR-mediated knock-in system and method of use [patent_app_type] => utility [patent_app_number] => 16/587405 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 16 [patent_no_of_words] => 9001 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16587405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336107 [patent_doc_number] => 20220002438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => MUSK INHIBITION [patent_app_type] => utility [patent_app_number] => 17/272791 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17272791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036781 [patent_doc_number] => 20210253739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => ANTICARBOXYMETHYL LYSINE ANTIBODIES AND ULTRASOUND FOR REMOVING AGE-MODIFIED CELLS [patent_app_type] => utility [patent_app_number] => 17/268413 [patent_app_country] => US [patent_app_date] => 2019-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17070 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17268413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258542 [patent_doc_number] => 20210371527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => ANTIGEN BINDING CONSTRUCTS TO CD4 [patent_app_type] => utility [patent_app_number] => 16/972724 [patent_app_country] => US [patent_app_date] => 2019-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32813 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688790 [patent_doc_number] => 20210071266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => Role of PVT1 in the Diagnosis and Treatment of MYC-Driven Cancer [patent_app_type] => utility [patent_app_number] => 17/053328 [patent_app_country] => US [patent_app_date] => 2019-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17053328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688392 [patent_doc_number] => 20210070868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => COMBINATION OF ANTI-HGFR ANTIBODY AND HEGFR FOR THE TREATMENT OF A TUMOR AND/OR METASTASIS [patent_app_type] => utility [patent_app_number] => 16/982330 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12843 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16622792 [patent_doc_number] => 20210041445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => METHODS FOR MONITORING TREATMENT RESPONSE AND DISEASE PROGRESSION IN SUBJECTS USING CIRCULATING CELLS [patent_app_type] => utility [patent_app_number] => 16/979742 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18931098 [patent_doc_number] => 11883492 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Combination treatment of chemoresistant cancers [patent_app_type] => utility [patent_app_number] => 16/979469 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 73 [patent_no_of_words] => 42102 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16557221 [patent_doc_number] => 20210002369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => ANTI-PD-1 ANTIBODY COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/978354 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19151235 [patent_doc_number] => 11976132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-07 [patent_title] => Diagnostic methods using anti-MUC1* antibodies [patent_app_type] => utility [patent_app_number] => 16/975625 [patent_app_country] => US [patent_app_date] => 2019-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 76 [patent_figures_cnt] => 234 [patent_no_of_words] => 22160 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16975625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18962904 [patent_doc_number] => 11896643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Fibroblast binding agents and use thereof [patent_app_type] => utility [patent_app_number] => 16/967288 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 27 [patent_no_of_words] => 58490 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1334 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16967288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621540 [patent_doc_number] => 20210040193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => ANTI-PD-1/ANTI-VEGF NATURAL ANTIBODY STRUCTURE LIKE HETERODIMERIC FORM BISPECIFIC ANTIBODY AND PREPARATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/968677 [patent_app_country] => US [patent_app_date] => 2019-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11381 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16968677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17650737 [patent_doc_number] => 11353460 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => L2A5 antibody or functional fragment thereof against tumour antigens [patent_app_type] => utility [patent_app_number] => 16/964900 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 8941 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17665340 [patent_doc_number] => 11359021 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof [patent_app_type] => utility [patent_app_number] => 16/960297 [patent_app_country] => US [patent_app_date] => 2019-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 10 [patent_no_of_words] => 17348 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 355 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16960297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18171735 [patent_doc_number] => 11571427 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment [patent_app_type] => utility [patent_app_number] => 16/958536 [patent_app_country] => US [patent_app_date] => 2018-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 76 [patent_figures_cnt] => 103 [patent_no_of_words] => 32616 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711913 [patent_doc_number] => 20210079060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => CD19 VARIANTS [patent_app_type] => utility [patent_app_number] => 16/954002 [patent_app_country] => US [patent_app_date] => 2018-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16507503 [patent_doc_number] => 20200386759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => ROBUST PANELS OF COLORECTAL CANCER BIOMARKERS [patent_app_type] => utility [patent_app_number] => 16/769544 [patent_app_country] => US [patent_app_date] => 2018-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37748 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16769544 [rel_patent_id] =>[rel_patent_doc_number] =>)